Cite
HARVARD Citation
D'Antoni, M. et al. (n.d.). 633. Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Efficacy in Participants with Pre-Existing Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials. Open forum infectious diseases. pp. S376-S377. [Online].